4242 Campus Point Court
Suite 500
San Diego
United States

Show jobs for this employer

This animation demonstrates the proposed mechanism of action for Tocagen’s lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC, and is based primarily on preclinical data.
Toca 511 & Toca FC is an investigational therapy, which has not been proven to be safe or effective for any use and is not approved by the U.S. Food and Drug Administration or any other government agency.
Tocagen is developing broadly applicable, cancer-selective immunotherapy treatments for cancer, including high grade glioma, a type of brain cancer. The company’s lead product combines Toca 511 with Toca FC. The therapeutic regimen involves two discrete steps with Toca 511 given first followed by treatment with Toca FC.  

109 articles with Tocagen